Document is current

Article History

Received: 9 July 2024

Revised: 13 September 2024

Accepted: 14 September 2024

First Online: 7 October 2024

Declarations

:

: MH receives funding from the National Institutes on Aging K01AG066971 and The Consolidated Anti-Aging Foundation. MH is a shareholder of Arena Therapeutics, a company focused on advancing research of DBS for the treatment of patients recently diagnosed with PD. DI receives funding from the National Institute of Neurological Disorders and Stroke (1K23NS131592-01) and from Teva Branded Pharmaceutical Products, R&D. DC is a shareholder of Arena Therapeutics, a company focused on advancing research of DBS for the treatment of patients recently diagnosed with PD. AH was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, 424778381—TRR 295), Deutsches Zentrum für Luft- und Raumfahrt (DynaSti grant within the EU Joint Programme Neurodegenerative Disease Research, JPND), the National Institutes of Health (R01 13478451, 1R01NS127892-01, 2R01 MH113929 & UM1NS132358) as well as the New Venture Fund (FFOR Seed Grant). AH reports lecture fees for Boston Scientific and is a consultant for FxNeuromodulation and Abbott. There are no additional disclosures to report for NR, KP, EA, SS, FTP, PH, TLD.

: This study was approved by the Vanderbilt Institutional Review Board. All subjects provided written informed consent to participate. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.